LZTS1 and ovarian carcinoma: Intriguingly, decreased expression of LZTS1 reflects a higher rate of complete response to platinum–taxane‐based chemotherapy than non‐taxane‐based treatment in patients with ovarian cancer,27 indicating that a decreased LZTS1 level favours chemotherapy response in ovarian cancer.